Lancet

BACKGROUND: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. METHODS: CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). INTERPRETATION: The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. FUNDING: American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3) : analysis of individual data from 258 cancer registries in 61 countries

Background Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0–14 years) and adults (aged 15–99 years) diagnosed with a haematological malignancy during 2000–14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0–24 years). Methods We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0–14 years), adolescents (15–19 years), and young adults (20–24 years). We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis. Findings 164563 young people were included in this analysis: 121328 (73·7%) children, 22963 (14·0%) adolescents, and 20272 (12·3%) young adults. In 2010–14, the most common subtypes were lymphoid leukaemia (28205 [68·2%] patients) and acute myeloid leukaemia (7863 [19·0%] patients). Age-standardised 5-year net survival in children, adolescents, and young adults for all leukaemias combined during 2010–14 varied widely, ranging from 46% in Mexico to more than 85% in Canada, Cyprus, Belgium, Denmark, Finland, and Australia. Individuals with lymphoid leukaemia had better age-standardised survival (from 43% in Ecuador to ≥80% in parts of Europe, North America, Oceania, and Asia) than those with acute myeloid leukaemia (from 32% in Peru to ≥70% in most high-income countries in Europe, North America, and Oceania). Throughout 2000–14, survival from all leukaemias combined remained consistently higher for children than adolescents and young adults, and minimal improvement was seen for adolescents and young adults in most countries. Interpretation This study offers the first worldwide picture of population-based survival from leukaemia in children, adolescents, and young adults. Adolescents and young adults diagnosed with leukaemia continue to have lower survival than children. Trends in survival from leukaemia for adolescents and young adults are important indicators of the quality of cancer management in this age group.peer-reviewe

Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000–2014 (CONCORD-3)

Background: Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. Methods: We analyzed individual data for adults (15–99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000–2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. Results: The study included 556,237 adults. In 2010–2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%–38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000–2004 and 2005–2009. These improvements were more noticeable among adults diagnosed aged 40–70 years than among younger adults. Conclusions: To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines

Composition and antimicrobial activity of the essential oils from flowers of Senecio othonnae, S. racemosus, and S. nemorensis

PubMed: 20521557The chemical composition of the essential oils of Senecio othonnae, S. racemosus, and S. nemorensis obtained by hydrodistillation of fresh flowers were analysed by GC-FID and GC-MS. A total of seventy-six compounds were identified, constituting over 83.1%, 97.7% and 86.8% of the total oil composition of the flowers of S. othonnae, S. racemosus, and S. nemorensis. The main components of the oils were caryophyllene oxide (18.6%), (E)-?-farnesene (21.6%), and ?-curcumene (42.8%), respectively. Sesquiterpene hydrocarbons were the main group of constituents of all three species, forming 34.6%, 73.2%, and 81.8% of the oils, respectively. The oils of S. othonnae, and S. nemorensis showed antimicrobial activity against Bacillus cereus, Staphylococcus aureus, Enterococcus faecalis, and Candida tropicalis, but that of S. racemosus was only active against Candida tropicalis

Chemical composition and antimicrobial activity of the essential oils of mosses (Tortula muralis Hedw., Homalothecium lutescens (Hedw.) H. Rob., Hypnum cupressiforme Hedw., and Pohlia nutans (Hedw.) Lindb.) from Turkey

The essential oils of mosses [Tortula muralis Hedw. (Pottiaceae), Homalothecium lutescens (Hedw.) H. Rob. (Brachytheciaceae), Hypnum cupressiforme Hedw. (Hypnaceae), and Pohlia nutans (Hedw.) Lindb. (Mniaceae)] were investigated by means of GC-FID/MS techniques. The major components were nonanal (18.3%) and tetradecanol (4.3%) in the oil of T. muralis, nonanal (36.8%) and tricosane (6.5%) in the oil of H. lutescens, nonanal (12.5%) and 2 E-tetradecen-1-ol (6.9%) in the oil of H. cupressiforme, and nonanal (7.8%) and 2 E-tetradecen-1-ol (7.1%) in the oil of P. nutans. The essential oils of T. muralis, H. lutescens, H. cupressiforme, and P. nutans were rich as in non-terpenoid components as aldehydes (26.9%, 50.9%, 15.6%, and 33.4%, respectively) and in terpenoid components as sesquiterpene hydrocarbons (6.7%, 11.0%, 12.7%, and 15.3%, respectively). The amounts and the numbers of terpenoids present in the investigated mosses are generally smaller than those in non-terpenoids. The isolated essential oils of T. muralis, H. lutescens, H. cupressiforme, and P. nutan were tested for antimicrobial activity against the bacteria Escherichia coli, Yersinia pseudotuberculosis, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, and Bacillus cereus, and the fungi Candida albicans and Saccharomyces cerevisiae at a maximum essential oil concentration of 27, 000-65, 000 ?g/mL in hexane, respectively, and they showed antimicrobial activity only against the fungi. © TÜBITAK

Photochemistry of nitro-substituted (E)-2-azachalcones with theoretical calculations and biological activities

Four new stereoselective dimerization products (4a-c, 5) of m- and p-nitro-substituted (E)-2-azachalcones (2 and 3) were synthesized and tested for antimicrobial and antioxidant activities. Compounds 1-3 showed very good antimicrobial activities against all the tested microorganisms, Escherichia coli, Yersinia pseudotuberculosis, Pseudomonas aeruginosa, Bacillus cereus, Listeria monocytogenes, Staphylococcus aureus, Enterococcus faecalis, and Candida albicans. Five of the compounds tested were radical scavengers with 50% scavenging concentration (SC50) values between 0.130 and 2.047 mg/mL. The monomeric o-nitro-substituted (E)-2-azachalcone (1) showed the highest 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity with the SC50 value of 0.130 mg/mL. Compound 3 was prooxidant and compound 4b was inactive in DPPH test. The higher antimicrobial activity of compound 1 was paralleled with its higher antioxidant activity, which makes it potential agent for the cure of bacterial infections concurrent with oxidative stress. The theoretical calculations based on transition state structures were made to obtain possible photochemical dimerization products of compounds 1-3. The expected dimeric products from calculations coincided with those experimentally produced. © 2009 Elsevier B.V. All rights reserved.Karadeniz Teknik Üniversitesi Consejo Nacional para Investigaciones Científicas y TecnológicasThis study was supported by grants from Karadeniz Technical University and the Scientific and Technological Research Council (TUBITAK) of Turkey